Social and Epidemiological Research Department, Centre for Addiction and Mental Health, University of Toronto, ON, Canada.
JAMA Psychiatry. 2013 Apr;70(4):436-43. doi: 10.1001/jamapsychiatry.2013.684.
Untreated depression during pregnancy has been associated with increased morbidity and mortality for both mother and child and, as such, optimal treatment strategies are required for this population.
There are conflicting data regarding potential risks of prenatal antidepressant treatment.
To determine whether prenatal antidepressant exposure is associated with risk for selected adverse pregnancy or delivery outcomes. DATA SOURCES MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature, PsycINFO, and the Cochrane Library were searched from their start dates to June 30, 2010. STUDY SELECTION English-language studies reporting outcomes associated with pharmacologic treatment during pregnancy were included. We reviewed 3074 abstracts, retrieved 735 articles, and included 23 studies in this meta-analysis.
Study design, antidepressant exposure, adjustment for confounders, and study quality were extracted by 2 independent reviewers.
There was no significant association between antidepressant medication exposure and spontaneous abortion (odds ratio [OR], 1.47; 95% CI, 0.99 to 2.17; P = .055). Gestational age and preterm delivery were statistically significantly associated with antidepressant exposure (mean difference [MD] [weeks], -0.45; 95% CI, -0.64 to -0.25; P < .001; and OR, 1.55; 95% CI, 1.38 to 1.74; P < .001, respectively), regardless of whether the comparison group consisted of all unexposed mothers or only depressed mothers without antidepressant exposure. Antidepressant exposure during pregnancy was significantly associated with lower birth weight (MD [grams], -74; 95% CI, -117 to -31; P = .001); when this comparison group was limited to depressed mothers without antidepressant exposure, there was no longer a significant association. Antidepressant exposure was significantly associated with lower Apgar scores at 1 and 5 minutes, regardless of whether the comparison group was all mothers or only those who were depressed during pregnancy but not exposed to antidepressants.
Although statistically significant associations between antidepressant exposure and pregnancy and delivery outcomes were identified, group differences were small and scores in the exposed group were typically within the normal ranges, indicating the importance of considering clinical significance. Treatment decisions must weigh the effect of untreated maternal depression against the potential adverse effects of antidepressant exposure.
未经治疗的孕期抑郁症与母婴发病率和死亡率的增加有关,因此需要为这一人群制定最佳的治疗策略。
关于产前抗抑郁药物治疗的潜在风险存在相互矛盾的数据。
确定产前抗抑郁药物暴露是否与特定不良妊娠或分娩结局的风险相关。
从开始日期到 2010 年 6 月 30 日,对 MEDLINE、EMBASE、护理学及相关健康学科累积索引、PsycINFO 和 Cochrane 图书馆进行了 MEDLINE、EMBASE、护理学及相关健康学科累积索引、PsycINFO 和 Cochrane 图书馆的检索。
报告与孕期药物治疗相关结局的英语文献包括在内。我们回顾了 3074 篇摘要,获取了 735 篇文章,并将 23 项研究纳入本荟萃分析。
由 2 名独立评审员提取研究设计、抗抑郁药暴露、混杂因素调整和研究质量。
抗抑郁药暴露与自然流产之间无显著相关性(比值比 [OR],1.47;95%置信区间,0.99 至 2.17;P =.055)。胎龄和早产与抗抑郁药暴露有统计学显著关联(周均值差异 [MD] [周],-0.45;95%置信区间,-0.64 至 -0.25;P <.001;OR,1.55;95%置信区间,1.38 至 1.74;P <.001),无论对照组是所有未暴露的母亲还是仅未接受抗抑郁药治疗的抑郁母亲。孕期抗抑郁药暴露与较低的出生体重显著相关(MD [克],-74;95%置信区间,-117 至 -31;P =.001);当将此对照组限于未接受抗抑郁药治疗的抑郁母亲时,不再存在显著相关性。抗抑郁药暴露与 1 分钟和 5 分钟时较低的 Apgar 评分显著相关,无论对照组是所有母亲还是仅在怀孕期间抑郁但未接受抗抑郁药治疗的母亲。
尽管确定了抗抑郁药暴露与妊娠和分娩结局之间存在统计学显著关联,但组间差异较小,暴露组的评分通常在正常范围内,表明需要考虑临床意义。治疗决策必须权衡未治疗的产妇抑郁与抗抑郁药暴露的潜在不良影响。